SynAct’s CSO on resomelagon making WHO’s dengue shortlist

2026-09-17 16:11:00

In a comprehensive global review published in Lancet Microbe, the World Health Organization has identified SynAct Pharma’s resomelagon as one of only six dengue therapeutic candidates with sufficient evidence to support further clinical development. Resomelagon is the only host-directed therapy in the group. BioStock contacted Thomas Jonassen, Chief Scientific Officer of Synact Pharma, for a comment.

Read the full interview at biostock.se:

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Read the latest news, keep track of upcoming events, explore BioStock Analytics' in-depth analyses and watch the latest videos! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the Nordic region's leading information channel for life science. Focusing on biotech, medtech, diagnostics and pharmaceutical development, we provide daily news updates, in-depth analyses via BioStock Analytics, exclusive interviews and innovation-driving networking events – all to keep you up to date on developments in the sector.
BioStock – Connecting Innovation & Capital.